摘要
目的:观察贝伐珠单抗联合奥沙利铂和希罗达治疗晚期结直肠癌的临床效果。方法:选取本院2018年5月-2019年5月的82例晚期结直肠癌患者为研究对象。采用隐匿数字随机法分为研究组和对照组,每组41例。对照组采用奥沙利铂和希罗达(XELOX方案)治疗,研究组在对照组基础上给予贝伐珠单抗治疗。比较两组总有效率、疾病控制率及毒副反应。患者均随访15个月,比较两组无进展生存时间。结果:研究组总有效率、疾病控制率分别为46.34%、82.93%,均高于对照组的21.95%、60.98%,差异均有统计学意义(P<0.05)。研究组中位无进展生存时间为10.73个月[95%CI(6.3,14.9)],对照组为7.26个月[95%CI(4.8,10.2)],差异有统计学意义(P<0.05)。研究组高血压发生率高于对照组,差异有统计学意义(P<0.05)。两组其他毒副反应发生率比较,差异均无统计学意义(P>0.05)。结论:采用贝伐珠单抗联合XELOX方案治疗晚期结直肠癌可提高有效率和疾病控制率,延长无进展生存时间,且患者对毒副反应可以耐受。
Objective:To observe the clinical effect of Bevacizumab combined with Oxaliplatin and Xeloda in the treatment of advanced colorectal cancer.Method:A total of 82 patients with advanced colorectal cancer in our hospital from May 2018 to May 2019 were selected as the research objects.The patients were divided into study group and control group by hidden number random method,41 cases in each group.Patients in the control group were treated with Oxaliplatin and Xeloda(XELOX regimen),and patients in the study group were treated with Bevacizumab on the basis of the control group.The total effective rate,disease control rate and toxic and side effects were compared between the two groups.All patients were followed up for 15 months,and progression-free survival time was compared between the two groups.Result:The total effective rate and disease control rate of the study group were 46.34%and 82.93%respectively,which were higher than 21.95%and 60.98%of the control group,the differences were statistically significant(P<0.05).The median progression free survival was 10.73 months[95%CI(6.3,14.9)],the control group was 7.26 months[95%CI(4.8,10.2)],the difference was statistically significant(P<0.05).The incidence of hypertension in the study group was higher than that in the control group,the difference was statistically significant(P<0.05).There were no significant differences in the incidence of other side effects between the two groups(P>0.05).Conclusion:Bevacizumab combined with XELOX regimen in the treatment of advanced colorectal cancer can improve the effective rate and disease control rate,prolong the progression free survival time,and patients can tolerate the toxicity.
作者
吕莉
邓明辉
郭立仪
LYU Li;DENG Minghui;GUO Liyi(Huizhou Sixth People’s Hospital,Huizhou 516211,China;不详)
出处
《中国医学创新》
CAS
2021年第6期42-45,共4页
Medical Innovation of China
